Cogent Biosciences' CGT1263 Pan-KRAS(ON) Inhibitor and CNS-Penetrant ErbB2 Inhibitor CGT4255 Preclinical Data at AACR 2026
Cogent Biosciences presents preclinical data for its novel pan-KRAS(ON) inhibitor CGT1263 and selective ErbB2 inhibitor CGT4255 at AACR 2026. CGT1263 shows best-in-class cellular potency with a kinase selectivity advantage that could mitigate skin toxicity plaguing multi-RAS inhibitors. CGT4255 is designed with best-in-class CNS penetration to address HER2+ brain metastases, with preclinical synergy data with a HER2 ADC suggesting re-sensitization after ADC resistance.